Pr BEPREVE™ 1.5%

HELP TREAT THE ITCH

ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS[1]

BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% w/v is indicated for the treatment of itching associated with allergic conjunctivitis.[1]

BEPREVE™ demonstrated significant reduction in ocular itching at 3 minutes post CAC[1–4,*]

Ocular itch scores at 3 minutes post CAC (both eyes averaged)



- At Visit 5 (15 minutes after instillation of BEPREVE™ 1.5% w/v), the mean difference in ocular itch score 3 minutes post CAC, compared to placebo, was 1.4 and 1.5 in Study A[2,4,§] and Study B[3,4,§], respectively

ORDER NOW!

PRODUCT SPECIFICATIONS

Product	Size	B&L SKU	DIN	UPC
BEPREVE™	5 mL	AC52107	02456532	0 24208 62902 3

WHOLESALE ORDER NUMBERS

McKesson	Kohl & Frisch
108644	157657

For more product information, please contact your local Bausch & Lomb Sales Representative or call Customer Service at 1-800-686-7720 (English) or 1-800-686-0002 (French).

Clinical use:

- The safety and efficacy of BEPREVE™ has not been established in pediatric patients under 3 years of age and should not be used in this population
- Efficacy of BEPREVE™ in pediatric patients with age <10 was extrapolated from clinical trials conducted in pediatric patients with age >10 and in adults

Relevant warnings and precautions:

- BEPREVE™ is for topical ophthalmic use only
- Do not touch the eyelids or surrounding areas with the dropper tip of bottle and keep bottle tightly closed when not in use
- BEPREVE™ should not be used to treat contact lens-related irritation
- BEPREVE™ should not be instilled while wearing contact lenses. BEPREVE™ contains benzalkonium chloride as a preservative, which may be absorbed by soft contact lenses. Remove contact lenses prior to instillation; lenses may be reinserted 10 minutes after the administration of BEPREVE™
- BEPREVE™ should not be used in pregnant women unless the benefit to the mother clearly outweighs the risk to the fetus
- Caution should be exercised when BEPREVE™ is administered to lactating women

For more information:

Please consult the Product Monograph at **http://www.bausch.ca/Portals/59/Files/Monograph/Pharma/bepreve-pm-en.pdf** for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling 1-888-459-5000.

* CAC = conjunctival allergen challenge

§ Both Studies A and B were phase III, double-masked, randomized, placebo-controlled CAC clinical trials in which patients were assigned to BEPREVE™ or placebo. Analysis used CAC model of allergic conjunctivitis (i.e., using multiple allergens, both seasonal and perennial). Ocular itching was graded by subjects using a 9-point scale (0–4 U, half units allowed). Primary endpoints included ocular itching with dose applied bilaterally 15 minutes, 8 hours, and 16 hours prior to challenge (measured 3, 5, and 7 minutes post CAC)[1–4]

References: 1. BEPREVE™ (bepotastine besilate ophthalmic solution 1.5%) Product Monograph. Bausch & Lomb Canada Inc.; July 22, 2016. **2.** Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. *Clin Ther* 2009;31:1908–21. **3.** Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. *Am J Ophthalmol* 2010;15:122–7. **4.** Data on file, Bausch & Lomb Incorporated, 2008.

BAUSCH + LOMB

Bausch & Lomb Canada, Vaughan, Ontario L4K 4B4

PAAB

Pr BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5%